Use of bi- and tri-specific T cell engager-armed OVs may indeed be the next advance in cancer immunotherapy.65 An OVV was created that encoded a secretory bispecific T cell engager consisting of two single-chain variable fragments for CD3 as well as the tumor cell surface antigen EphA2 (EphA2-TEA-VV).66 Tumor cells infected with EphA2-TEA-VV induced T cell activation. The gene discussed is EPHA2; the disease is neoplasm.